Status:
TERMINATED
A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase Inhibitor In Patients With Advanced Cancer
Lead Sponsor:
Pfizer
Conditions:
Neoplasms
Lymphoma, Non-Hodgkin
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
AG-024322 may work in cancer by stopping cancer cells from multiplying. AG-024322 is and intravenous drug from a new class of drugs call cyclin-dependent kinase (CDK inhibitors). This research study i...
Detailed Description
The study was prematurely discontinued due to the inability of the compound to adequately differentiate from other treatment options in the clinical endpoint and necessary product profile on April 13,...
Eligibility Criteria
Inclusion
- Advanced solid tumors or follicular of diffuse large cell non-Hodgkin's lymphoma, histologically or cytologically proven at diagnosis which is refractory to or intolerant of established therapy know to provide clinical benefit for their condition
- Adequate blood cell counts, kidney function and liver function and and ECOG score of 0 or 1.
Exclusion
- Prior high-dose chemotherapy requiring hemapoietic stem cell rescue
- Previous radiation therapy to \>25% of the bone marrow
- Active or unstable cardiac disease or history of heart attack within 6 months
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2007
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT00147485
Start Date
December 1 2004
End Date
August 1 2007
Last Update
August 18 2008
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Boston, Massachusetts, United States, 02114
2
Pfizer Investigational Site
Boston, Massachusetts, United States, 02115
3
Pfizer Investigational Site
Boston, Massachusetts, United States, 02215
4
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States, 19104